Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Learn More

Your Location is set to:

CompassHER2 Residual Disease for Breast Cancer

THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB -- NCT04457596

Objective

A clinical trial to determine if invasive disease free survival with Kadcyla and tucatinib is superior to Kadcyla and placebo when given to high risk patients with HER2 positive breast cancer and residual disease after HER2-directed therapy.

Principal Investigator(s)
Edward Wyluda, DO

Clinical Trial Categories

  • Treatment
  • Breast Cancer
Contact
Christine Neely-Jones, RN at 508-862-7298
or cneelyjones@capecodhealth.org
How to Participate

Contact your oncologist, oncology nurse or the Oncology Research Program Manager.